ASRS 2023: Megan Baldwin, CEO of Opthea Limited, shares updates on sozinibercept

News
Video

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at ASRS 2023.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Megan Baldwin, PhD:

Hello, I'm Megan Baldwin. I'm CEO and managing director of Opthea Limited. Opthea Limited is here at the ASRS, in Seattle. We will have a presentation by Dr Dante Pierramici on Monday of this week at ASRS. He'll be talking about OPT-302, which is also just announced to be called sozinibercept. Though he'll be talking about the pharmacokinetic and safety data that we've demonstrated with the molecule to date. We are currently in phase 3 clinical development, recruiting patients globally for our product, which is in development in combination with both Eylea, or aflibercept, as well as Lucentis ranibizumab. And the objective of our approach is to provide additional clinical benefit visual acuity improved outcomes for patients on top of standard of care.

It will mean that ophthalmologist physicians worldwide have an additional therapeutic option for patients in order to improve their clinical outcomes, which I think is the number one unmet medical need for patients right now. Right now, there's very limited treatment options. We understand that the VEGF-A inhibitors are a very clinically, you know, commercially successful class of drugs. But the fact is that many, many patients actually don't respond optimally, and that there's additional opportunity to provide visual acuity benefit across the board for many, many patients worldwide. And that's what we want to do with sozinibercept, OPT-302, which is a molecule that achieves a broader blockade of the validated pathways in the disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.